De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Galmed Pharmaceuticals Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Allen Baharaff
Algemeen directeur
US$1.4m
Totale compensatie
| Percentage CEO-salaris | 40.6% |
| Dienstverband CEO | 24.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 7.6yrs |
| Gemiddelde ambtstermijn bestuur | 8.8yrs |
Recente managementupdates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$6m |
| Mar 31 2024 | n/a | n/a | -US$6m |
| Dec 31 2023 | US$1m | US$551k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$11m |
| Mar 31 2023 | n/a | n/a | -US$14m |
| Dec 31 2022 | US$1m | US$605k | -US$18m |
| Sep 30 2022 | n/a | n/a | -US$23m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$30m |
| Dec 31 2021 | US$3m | US$632k | -US$32m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$503k | -US$29m |
| Sep 30 2020 | n/a | n/a | -US$27m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$1m | US$486k | -US$20m |
| Sep 30 2019 | n/a | n/a | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$12m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$2m | US$384k | -US$10m |
| Sep 30 2018 | n/a | n/a | -US$10m |
| Jun 30 2018 | n/a | n/a | -US$12m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$1m | US$384k | -US$12m |
Compensatie versus markt: De totale vergoeding ($USD 1.36M ) Allen } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 667.78K ).
Compensatie versus inkomsten: De vergoeding van Allen is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Allen Baharaff (59 yo)
24.8yrs
Tenure
US$1,356,184
Compensatie
Mr. Allen Baharaff has been the Chief Executive Officer of Galmed Pharmaceuticals Ltd. since January 2012 and has been its President since March 2015. Mr. Baharaff co-founded the Galmed Pharmaceuticals Ltd...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 24.8yrs | US$1.36m | geen gegevens | |
| Chief Financial Officer | 2.7yrs | US$273.81k | 0.0026% $ 98.9 | |
| COO & Data Protection Officer | 7.6yrs | US$374.78k | 0.0048% $ 180.6 | |
| Chief Accounting Officer | 2.7yrs | US$378.32k | 0.0048% $ 180.6 | |
| Chief Scientific Officer | 8.1yrs | US$114.69k | 0% $ 0 | |
| Medical Consultant | 7.6yrs | US$382.51k | geen gegevens |
7.6yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GLMD is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.6 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | no data | US$1.36m | geen gegevens | |
| Lead Independent Director | 10.3yrs | geen gegevens | 0.0065% $ 244.3 | |
| Independent Director | 7.3yrs | geen gegevens | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 17.8yrs | geen gegevens | 0.0065% $ 244.3 | |
| Independent Director | 4.3yrs | geen gegevens | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens |
8.8yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GLMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).